Kohichiro
Kohichiro Shiraishi, Shinjuku-Ku JP
Patent application number | Description | Published |
---|---|---|
20100292066 | GLASS MATERIAL FOR MOLD PRESSING, METHOD FOR MANUFACTURING SAME, AND METHOD FOR MANUFACTURING OPTICAL GLASS ELEMENT - A glass material for mold pressing, comprised of a core portion comprised of a multicomponent optical glass containing at least one readily reducible component selected from among W, Ti, Bi, and Nb, and a covering portion covering the surface of said core portion, comprised of a multicomponent glass containing none or a lower quantity of said readily reducible component than is contained in said core portion. A glass material for mold pressing comprising a core portion comprised of a fluorine-containing multicomponent optical glass and a covering portion covering the surface of said core portion, comprised of a multicomponent glass containing none or a lower quantity of fluorine than is contained in said core portion. A method for manufacturing an optical glass element comprising heat softening a glass material that has been preformed into a prescribed shape, and conducting press molding with a pressing mold, employing the above glass material of the invention. To provide a stable production of optical elements affording adequate optical performance by using optical glass containing readily reducible components or fluorine and inhibiting undesirable interface reactions during press molding. | 11-18-2010 |
Kohichiro Tsuji, Minato-Ku JP
Patent application number | Description | Published |
---|---|---|
20150104820 | METHOD FOR PRODUCTION OF EOSINOPHIL FROM PLURIPOTENT STEM CELL - The present invention relates to a method for producing human eosinophils from human pluripotent stem cells. More specifically, the present invention provides a method for producing human eosinophils from human pluripotent stem cells, which method comprises the steps of: (1) co-culturing, in the presence of VEGF, human pluripotent stem cells with cells separated from the AGM region of a mammalian fetus; (2) performing suspension culture using a medium comprising IL-3, IL-6, Flt3 ligand, SCF, TPO and serum; (3) performing suspension culture using a medium comprising IL-3, SCF, GM-CSF and serum; and, optionally, (4) performing suspension culture using a medium comprising IL-3, IL-5 and serum. | 04-16-2015 |
Kohichiro Watanabe, Annaka-Shi JP
Patent application number | Description | Published |
---|---|---|
20100243951 | NEGATIVE ELECTRODE MATERIAL FOR NONAQUEOUS ELECTROLYTE SECONDARY BATTERY, MAKING METHOD AND LITHIUM ION SECONDARY BATTERY - A negative electrode material comprising composite particles having silicon nano-particles dispersed in silicon oxide is suited for use in nonaqueous electrolyte secondary batteries. The silicon nano-particles have a size of 1-100 nm. The composite particles contain oxygen and silicon in a molar ratio: 009-30-2010 | |
Kohichiro Yasui, Kyoto JP
Patent application number | Description | Published |
---|---|---|
20090143236 | Method of detecting cancer cell acquiring drug-resistance - It is an object of the present invention to find out a novel gene marker by which a drug-resistant cancer cell can be detected and provide a means of efficiently and comprehensively detecting a drug-resistant cancer cell using this marker. In the present invention, gene amplifications or deletions have been analyzed in cancer cell strains resistant to drugs, which are anticancer drugs having particularly serious side effects and being administered to cancer patients at a high frequency (namely, camptothecins, cisplatins, etoposides, adriamycins (ADM), and cytosine arabinosides), and parent cancer cell strains. As a result, it was found out that the acquisition of drug-resistance to an anticancer drug in a test cancer cell can be detected by detecting amplification of one or more genes selected from ABC transporter genes and BCL2 family genes consisting of ABCA3 gene, ABCB6 gene, ABCB8 gene, ABCB10 gene, ABCC4 gene, ABCC9 gene, ABCD3 gene, ABCD4 gene, ABCE1 gene, ABCF2 gene, BCL2L2, BCL2L10, BCL2L1, and BCL2A1 which are novel gene markers relating to the acquisition of drug resistance of cancer cells. | 06-04-2009 |